Nanose Medical

Nanose Medical Overview

Delivering affordable, accurate point-of-care screening—transforming timely insights into improved risk stratification and better patient outcomes Liver disease (MASLD/MASH) and lung cancer are often fatal because they're detected late, when treatment options are limited. Most solutions are invasive, expensive, or underused, so about 83% of MASLD cases go undiagnosed and only 5% of those at risk for lung cancer are screened. Low trust, hesitant prescribers, and payer resistance cause further delays and misdirected care. We’ve developed a non-invasive AI-driven breath-sensing device detecting unique biomarker fingerprints with current application for screening for lung cancer and MASH advanced liver fibrosis screening, detecting unique biomarker fingerprints. With thousands of samples and clinical data collected from 10 sites, our tech shows 80% accuracy . higher accuracy than current existing tools. Sample collection takes 30 seconds and evaluation takes 5 minutes. Accessible and scalable, it addresses critical gaps in screening and risk stratification, where current solutions fall short. Backed by Horizon EU, EIC-Transition, the IIA, and Google, we’re rapidly advancing population health solutions. For Value-Based-Care Organizations: reduces unnecessary referrals (currently ~90%) delivers $3M cost saving per ACO on average and $10B in total for medicare. It streamlines workflows with a simple 2 min process and enhances both patient and user experience, leading to higher testing compliance. By enabling early detection and intervention, it reduces long-term costs of $20k–70k per patient. For Pharma: Unlocks underdiagnosed patient populations, builds real-world evidence to accelerate reimbursement and adoption, and increases physician trust by providing actionable results—optimizing trial stratification and ensuring therapies reach the right patients.

Cumulative Funding Raised Over Time ($)

Latest News

Jun 9, 2025 · www.calcalistech.com

growth-positive

Backed by Google, the EU, and the IIA, NaNose Medical is pioneering non-invasive, breath-based diagnostics to close the gap in early detection of liver and lung cancer. As it approaches its Series A, co-founder and COO Ilay Marom says the Israeli startup is already eyeing real-world deployment and commercialization.

NaNose Medical, an Israeli startup backed by Google, the EU, and the Israeli Innovation Authority, is pioneering non-invasive, breath-based diagnostics for early detection of liver and lung cancer. The company is preparing for its Series A funding round, aiming to commercialize its technology that uses AI to analyze breath biomarkers. Despite a setback due to geopolitical tensions, NaNose received emergency support from the Israel Innovation Authority and Google. The company focuses on addressing diagnostic blind spots in conditions like MASLD, which affects a significant portion of the global population. NaNoses technology, inspired by the human olfactory system, offers a cost-effective alternative to traditional methods, with the potential to enhance patient outcomes and penetrate the primary care market.

InvestmentProduct Stage

May 13, 2025 · www.calcalistech.com

growth-positive

Ilay Marom, co-founder and COO of the startup NaNose Medical, was speaking on a panel held at Google and Calcalist’s Startup Week. Yair Levy, Brain.space: "I think Israel—its people and its tech ecosystem—has proven its resilience and creativity."

NaNose Medical, a startup specializing in early disease diagnosis through exhaled breath biomarkers, showcased its resilience during a panel at Google and Calcalist’s Startup Week. Despite the challenges posed by the October 7 crisis, the company managed to stabilize financially with grants from the European Union, Israel Innovation Authority, and Google. The team demonstrated extraordinary adaptability, advancing their development timeline despite disruptions. The panel emphasized the importance of resilience, adaptability, and choosing the right team members during times of uncertainty. NaNose Medical is currently in the clinical trial stage, collecting data in ten hospitals with promising results for diagnosing diseases like lung cancer.

Product StageInvestmentPartners

Jan 1, 2025 · easl.eu

“Novel point-of-care, rapid breath test to identify patients with metabolicdysfunction associated steatotic liver disease with advanced fibrosis – a pilot study” – poster published at the EASL SLD Summit 2025 Find the abstract on page 37

Jan 31, 2022 · www.themarker.com

growth-positive

ה"אף האלקטרוני" יציל חיים: החיישנים הננו-מטריים יתריעו על מחלות וזיהומים באמצעות הרחה בלבד

Nanose Medical, an Israeli company, is developing a diagnostic test that can detect diseases through breath analysis. The companys electronic nose technology is based on the principle that diseases have unique smells due to the release of specific volatile organic compounds (VOCs) from cells. The device collects a breath sample, exposes it to sensors, and then uses an algorithm to identify patterns in the electrical signals received. The company is currently in the development and clinical trial stage, with the first clinical trial conducted with three hospitals. The company believes that this non-invasive test could revolutionize the medical world by providing a cost-effective and efficient diagnostic tool.

InvestmentExpand

Jun 19, 2020 · www.timesofisrael.com

With a breath, Technion device finds lung cancer

Funding

Team Members

4

Employees: 1-10

Web & Social Links

Locations

Israel

Photos & Videos

7 item(s)

Nanose Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info